Atlas Venture
Onward & Upward: A look back at 2020 and to the future at Atlas Venture
Fund XII cClosed at $400M Hard Cap
3 Exciting Atlas Team Announcments

1 NEW PARTNER
Michael Gladstone

Michael Gladstone
Promoted to Partner

2 NEW TEAM MEMBERS
Rajesh Devraj, PhD

Rajesh Devraj, PhD
Re-joined as Venture Partner
Aimee Raleigh, PhD

Aimee Raleigh, PhD
Joined as Associate
4 M&A Events Totaling > $2.5B in Potential Value
Cadent Therapeutics

ACQUIRED BY
NOVARTIS

 Disarm Therapeutics

ACQUIRED BY
ELI LILLY

 LTI Therapeutics

ACQUIRED BY
BIAL

 Vedere

ACQUIRED BY
NOVARTIS
4 IPOs/SPACs Raising > $800M
Dyne Therapeutics Gemini Generation Bio Kymera
At Atlas, we build biotech companies from the ground-up with inspiring life science entrepreneurs. See our approach in action:

PRACTICING SCIENCE-FIRST VENTURE CREATION
11 New Portfolio Companies Launched in 2020, Collectively Raising > $600M In Seed and Series A Financings
Aerovate Affinia
Be Biopharma Day One Biopharmaceuticals
Kinaset Q32Bio
QuenchBio Remix Therapeutics
Scorpion Therapeutics Vedere
Vigil Neuro
Launched Nautilus Program - A Leadership Community For Atlas Portfolio CEOs
>40 Executives Recruited in 2020. Meet a few of our newest EIRs
Ivana Magovcevic-Liebisch, PhD, JD

Ivana Magovcevic-Liebisch, PhD, JD

President and CEO
Vigil Neuroscience
Vic Myer

Vic Myer

President and CSO
Chroma Medicine
Lisa Percival

Lisa Percival

Senior Vice President of Regulatory Affairs
Stealth Atlas NewCo
Simon Read

Simon Read

Entrepreneur-in-Residence
Atlas
>200 Active Job Postings Across the Atlas Portfolio. Find youy next opportunity here.

ADVANCING THERAPEUTIC PROGRAMS WITH NEW
CAPITAL AND STRATEGIC COLLABORATIONS
6 Companies Raised >$500M in Series B and Later Private Financings
Accent Therapeutics Dyne Therapeutics Generation Bio
HotSpot Therapeutics Kymera Q32Bio
12 Public Companies Raised >$1.8B in Follow-On Capital
Akero Avrobio
Bicycle Therapeutics Cogent Biosciences
Intellia Therapeutics Larimar Therapeutics
Magenta Therapeutics miRagen
Replimune Spero Therapeutics
Surface Oncology Translate Bio
7 Companies Established Significant Collaborations with Biopharma Partners
Accent Therapeutics & AstraZeneca
Affinia Therapeutics & Vertex
Kymera & Sanofi
Magenta Therapeutics & BluebirdBio
Navitor Pharmaceuticals & Supernus Pharmaceuticals
Surface Oncology & GSK
Translate Bio & Sanofi
We Moved | 300 Technology Square, 8th Floor, Cambridge, MA 02139
Atlas Perspectives

Leading and Learning Through Challenging World Events

From the Trenches post by Jodie Morrison, CEO of Cadent Therapeutics
READ ARTICLE

The Power of Hope: A Joint Perspective on Finding Balance in the Search for Life-Changing Therapies

From the Trenches post by Josh Brumm, CEO of Dyne Therapeutics, and Joachim Boekelmann, DM1 Patient Advocate
READ ARTICLE

The Record-Breaking Biotech Funding Tsunami Of 1H2020

LifeSciVC post by Bruce Booth
READ ARTICLE

Evolution of the Biotech IPO Markets from Busted to Booming

LifeSciVC post by Bruce Booth
READ ARTICLE

It's Raining Biotech SPACs!

LifeSciVC post by Bruce Booth
READ ARTICLE
Atlas Venture www.atlasventure.com Twitter